India to Maldives: Adalimumab Export Trade Route

To import finished pharmaceutical formulations containing Adalimumab into the Maldives, compliance with the Maldives Food and Drug Authority (MFDA) regulations is mandatory. The MFDA requires a comprehensive dossier submission, typically in the Common Technical Document (CTD) format, encompassing modules on quality, safety, and efficacy. The approval timeline varies based on the completeness of the submission and the complexity of the product but generally ranges from 6 to 12 months. Product registration fees are determined by the MFDA and are subject to periodic updates; applicants should consult the MFDA directly for the most current fee structure.

For manufacturing facilities located in India, the MFDA mandates evidence of Good Manufacturing Practice (GMP) compliance. This includes a valid GMP certificate issued by a recognized authority, such as the Central Drugs Standard Control Organisation (CDSCO) in India. The MFDA may also require a Site Master File detailing the facility's layout, equipment, and quality management systems. While the MFDA recognizes GMP certifications from PIC/S member countries, it reserves the right to conduct its own inspections or request additional documentation to ensure compliance with its standards.

Indian exporters of Adalimumab formulations must adhere to stringent GMP standards to qualify for supply to the Maldives. The MFDA requires that manufacturing facilities possess a valid GMP certificate from a recognized authority, such as the CDSCO. Additionally, the MFDA may request a Site Master File and other relevant quality documentation.

As of December 2025, the CDSCO, in collaboration with state drug controllers, conducted risk-based inspections of over 960 pharmaceutical manufacturing premises in India. These inspections led to more than 860 regulatory actions, including show cause notices, production stoppages, and license suspensions or cancellations. This underscores the Indian regulatory authorities' commitment to enforcing GMP compliance.

The MFDA maintains a vigilant stance on the quality of imported pharmaceuticals. In October 2024, the MFDA confirmed that none of the Indian medicines flagged for quality concerns had been imported into the Maldives. This proactive approach highlights the MFDA's dedication to ensuring that only products meeting its quality standards enter the Maldivian market.

Between 2024 and 2026, several regulatory developments have impacted Indian pharmaceutical exports to the Maldives:

• December 2023: The Indian Ministry of Health and Family Welfare revised Schedule M of the Drugs Rules, aligning India's GMP standards more closely with those of the World Health Organization (WHO). This amendment mandates enhanced quality controls across manufacturing processes to bolster drug safety and prevent adulteration.

• June 2025: The CDSCO directed all drug controllers in India to ensure that manufacturing units submit applications for WHO-GMP certificates and Certificates of Pharmaceutical Product (COPP) exclusively through the Online National Drugs Licensing System portal. This move aims to streamline the certification process and enhance regulatory oversight.

• December 2025: The CDSCO, in collaboration with state drug controllers, conducted risk-based inspections of over 960 pharmaceutical manufacturing premises in India. These inspections resulted in more than 860 regulatory actions, including show cause notices, production stoppages, and license suspensions or cancellations, emphasizing the commitment to GMP compliance.

These developments reflect a concerted effort by Indian regulatory authorities to enhance pharmaceutical manufacturing standards, which in turn supports the quality of exports to markets like the Maldives.

As of 2025, the global Adalimumab market was valued at USD 14.96 billion and is projected to grow to USD 20.09 billion by 2031, with a compound annual growth rate (CAGR) of 5.05% from 2026 to 2031. While specific data for the Maldives is limited, the country's demand for Adalimumab formulations is driven by the prevalence of autoimmune diseases, an aging population, and healthcare spending. The Maldives primarily relies on imports for its pharmaceutical needs, including Adalimumab formulations, due to limited domestic manufacturing capabilities.

Pharmaceutical products classified under HS code 30021500, including Adalimumab formulations, are subject to a 0% import duty in the Maldives. This exemption aligns with the country's policy to facilitate access to essential medications. Additionally, there are no anti-dumping duties or other charges imposed on these pharmaceutical imports. The Maldives and India have a longstanding trade relationship, but there is no specific Free Trade Agreement (FTA) affecting pharmaceutical tariffs between the two countries.

India is a significant supplier of Adalimumab formulations to the Maldives, accounting for 1.2% of India's total Adalimumab formulation exports, valued at $1.2 million. The top Indian exporters include MEDIX, NU HOSPITALS PRIVATE LIMITED, FEDELTY HEALTHCARE PRIVATE LIMITED, VEA IMPEX (I) PRIVATE LIMITED, and MEDIINOVA. Major buyers in the Maldives are STATE TRADING ORGANIZATION PLC, INDIRA GANDHI MEMORIAL HOSPITAL, and TREE TOP HEALTH PVT LIMITED. Other countries supplying Adalimumab formulations to the Maldives include Germany, Belgium, and the Netherlands. India's pricing for Adalimumab formulations is generally competitive compared to European manufacturers, offering cost-effective options for the Maldivian market.

India's pharmaceutical industry is renowned for its large-scale production of generic medicines, accounting for a significant portion of the global supply. As of November 2024, India maintained its position as the leading country with 396 FDA-registered generic drug manufacturing facilities, surpassing other nations in both API and finished dosage form (FDF) production. Specifically, India had 134 facilities dedicated to FDF manufacturing, reflecting its robust capacity in this sector.

The country's cost structure offers a competitive advantage, particularly in the production of complex formulations like Adalimumab. Indian manufacturers benefit from economies of scale, lower labor costs, and a well-established supply chain, enabling them to produce high-quality medications at reduced prices. Additionally, numerous Indian pharmaceutical plants hold certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and approvals from the U.S. Food and Drug Administration (FDA), ensuring compliance with stringent international quality standards.

When comparing Adalimumab formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: Indian manufacturers offer Adalimumab formulations at competitive prices. For instance, export data indicates that Adalimumab injections were priced at approximately $4.99 per unit in shipments to Zambia. In contrast, biosimilars in China are priced at about 82% of the reference drug's cost, reflecting a higher price point. EU-produced Adalimumab formulations, often branded generics, typically command higher prices due to brand value and stringent regulatory environments.

• Quality Perception: Indian pharmaceutical products are widely accepted globally, with many facilities holding WHO-GMP and FDA approvals. This ensures adherence to international quality standards. Chinese manufacturers have been expanding their FDA-registered facilities, indicating improvements in quality standards. EU manufacturers are traditionally associated with high-quality pharmaceutical products, benefiting from rigorous regulatory oversight.

• Regulatory Acceptance in Maldives: Maldives' regulatory authorities recognize and accept pharmaceuticals from India, given the established trade relations and compliance with international standards. Chinese and EU products are also accepted, but Indian formulations often have a more established presence in the Maldivian market.

• Supply Reliability Track Record: Indian manufacturers have a strong track record of reliable supply chains, supported by extensive manufacturing capacities and established logistics networks. Chinese manufacturers are improving in this regard, while EU manufacturers maintain consistent supply chains, albeit at higher costs.

The India-Maldives supply chain for Adalimumab formulations is characterized by:

• Manufacturing Capacity: India's substantial number of FDA-registered FDF facilities, totaling 134 as of November 2024, underscores its capability to meet large-scale demands.

• Packaging and Cold Chain Capabilities: Indian manufacturers have developed robust packaging and cold chain logistics to ensure the stability and efficacy of biologic formulations like Adalimumab during transit.

• Regulatory Compliance Track Record: Indian pharmaceutical companies have a history of adhering to international regulatory standards, with many facilities holding WHO-GMP and FDA certifications.

• Capacity Constraints or Expansion Plans: While specific data on capacity constraints or expansion plans among top Indian formulation manufacturers is limited, the continuous growth in FDA-registered facilities suggests ongoing investments in expanding manufacturing capabilities.

For Maldivian buyers sourcing Adalimumab from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Adalimumab formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, considering common practices in India-Maldives pharmaceutical trade, such as letters of credit or advance payments, to build trust and ensure timely deliveries.

• Supplier Qualification Process: Implement a rigorous supplier qualification process, including audits of manufacturing facilities, verification of regulatory certifications (e.g., WHO-GMP, FDA approvals), and assessment of quality control measures.

• Regulatory Compliance: Ensure that the selected suppliers comply with both Indian and Maldivian regulatory requirements, facilitating smooth importation and distribution within Maldives.

By adopting these strategies, Maldivian buyers can effectively source high-quality Adalimumab formulations from India, ensuring both cost-effectiveness and supply reliability.

By meticulously following these guidelines, Maldivian buyers can ensure the selection of reputable Indian Adalimumab manufacturers, thereby safeguarding public health and maintaining regulatory compliance.